{
  "id": "animeshparikshya/market-share-of-pharma-company-imaginary",
  "id_no": 1172609,
  "datasetSlugNullable": "market-share-of-pharma-company-imaginary",
  "ownerUserNullable": "animeshparikshya",
  "usabilityRatingNullable": 0.9411764705882353,
  "titleNullable": "Market Share of Pharma Company (imaginary) ",
  "subtitleNullable": "Data for market share of pharma company and data for 1 from 2011 till 2020. ",
  "descriptionNullable": "### Context\n\nI got this data as part of BIT's Mesra competition of Business Analysis Case Study in Feb 2021. \n\n### Content\n\nThis data set contains two csv fine with its individual description\n\n### Acknowledgements\n\nThank you BIT's Mesra, and my team Extra Miles \n\n### Inspiration\n\nBy this we want to know few Business Analysis problem statement:- \n\nTask - Prediction of Market Share of ChemX Pharma in current Pandamic\u00b6\n**Given Problem Statement - 1a)**\nA. What will be the market Share of Chem-X and the top 10 companies in 2021?\nNote:\ni. The top 10 companies will individually lose 2.2% of its revenue generated in 2020. The half (50%) of the lost revenue will go to \u2018Chem-X\u2019 and the rest to the others.\nii. The revenue generated by a company is proportional to its market share.\n\n**Given Problem Statement - 1b)**\nB. Also calculate the revenue generated by Chem-X in 2021 if the overall revenue generation for individual companies is increased by 5% of that in 2020.\n\n**Given Problem Statement - 2)**\nThere was another competitor (Medical MoJo) which was established in 2010 and had the same profile and outlook as Chem-X.\nHow much revenue ChemX will be able to generate in 2031, considering ChemX grows at an average growth rate (across 10 years) as Medical MoJo.\nNote:\nThe revenue for ChemX for 2021 to be leveraged from Question-1.1.\nWe expect a higher uptake (about 1.5) in the average growth from 2026, (not for subsequent years).\nAnother major competitor launch is planned for 2029 which leads to an expected slowdown in growth for ChemX and revenue is expected to become stagnant from 2028 onwards.",
  "datasetId": 1172609,
  "datasetSlug": "market-share-of-pharma-company-imaginary",
  "hasDatasetSlug": true,
  "ownerUser": "animeshparikshya",
  "hasOwnerUser": true,
  "usabilityRating": 0.9411764705882353,
  "hasUsabilityRating": true,
  "totalViews": 3804,
  "totalVotes": 10,
  "totalDownloads": 393,
  "title": "Market Share of Pharma Company (imaginary) ",
  "hasTitle": true,
  "subtitle": "Data for market share of pharma company and data for 1 from 2011 till 2020. ",
  "hasSubtitle": true,
  "description": "### Context\n\nI got this data as part of BIT's Mesra competition of Business Analysis Case Study in Feb 2021. \n\n### Content\n\nThis data set contains two csv fine with its individual description\n\n### Acknowledgements\n\nThank you BIT's Mesra, and my team Extra Miles \n\n### Inspiration\n\nBy this we want to know few Business Analysis problem statement:- \n\nTask - Prediction of Market Share of ChemX Pharma in current Pandamic\u00b6\n**Given Problem Statement - 1a)**\nA. What will be the market Share of Chem-X and the top 10 companies in 2021?\nNote:\ni. The top 10 companies will individually lose 2.2% of its revenue generated in 2020. The half (50%) of the lost revenue will go to \u2018Chem-X\u2019 and the rest to the others.\nii. The revenue generated by a company is proportional to its market share.\n\n**Given Problem Statement - 1b)**\nB. Also calculate the revenue generated by Chem-X in 2021 if the overall revenue generation for individual companies is increased by 5% of that in 2020.\n\n**Given Problem Statement - 2)**\nThere was another competitor (Medical MoJo) which was established in 2010 and had the same profile and outlook as Chem-X.\nHow much revenue ChemX will be able to generate in 2031, considering ChemX grows at an average growth rate (across 10 years) as Medical MoJo.\nNote:\nThe revenue for ChemX for 2021 to be leveraged from Question-1.1.\nWe expect a higher uptake (about 1.5) in the average growth from 2026, (not for subsequent years).\nAnother major competitor launch is planned for 2029 which leads to an expected slowdown in growth for ChemX and revenue is expected to become stagnant from 2028 onwards.",
  "hasDescription": true,
  "isPrivate": false,
  "keywords": [
    "healthcare",
    "business",
    "time series analysis",
    "text"
  ],
  "licenses": [
    {
      "nameNullable": "CC0-1.0",
      "name": "CC0-1.0",
      "hasName": true
    }
  ],
  "collaborators": [],
  "data": []
}